Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Core Insights - Optinose reported a fourth quarter 2024 net revenue of $22.4 million for XHANCE, representing a 13% increase year-over-year, and a full year revenue of $78.2 million, a 10% increase compared to the previous year [1][3] - The company experienced a 23% growth in total prescriptions from the third quarter to the fourth quarter of 2024, with new prescriptions increasing by 12% during the same period [2][3] Financial Performance - For Q4 2024, net revenue from XHANCE was $22.4 million, up from $19.9 million in Q4 2023, while the full year revenue rose from $71.0 million in 2023 to $78.2 million in 2024 [3] - Research and development expenses for Q4 2024 were $0.8 million, and for the full year, they totaled $3.9 million. Selling, general, and administrative expenses were $19.3 million for Q4 and $83.5 million for the full year [4] - The company reported an income from operations of $0.4 million for Q4 2024, marking the first time it achieved this in a three-month period, while the net loss for the quarter was $0.4 million [5] Balance Sheet - As of December 31, 2024, the company had cash and cash equivalents amounting to $84.5 million, an increase from $73.7 million in the previous year [6][9] - Total assets were reported at $128.8 million, with total current liabilities at $162.8 million, indicating a stockholders' deficit of $40.4 million [9]